In addition, we can determine if AAT modulation affects the outcome of smoking-induced lung injury and acute COPD exacerbation in assessing the overall feasibility for using AAT ASO for treatment of liver disease in patients with a predisposition to proteolytic lung destruction. This evidence concerns the gene SERPINA1 and chronic obstructive pulmonary disease.